Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post Transplant Cyclophosphamide for GvHD Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation
NCT03818334Phase 3Recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Hospital Israelita Albert Einstein. Started Nov 2018; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03818334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818334.